International Journal of Clinical Pharmacy
Fecha de publicación: January, 2021
Autores: Prof Monique L den Boer, PhD *, Prof Gunnar Cario, MD *, Prof Anthony V Moorman, PhD *, Judith M Boer, PhD, Hester A de Groot-Kruseman, PhD, Marta Fiocco, PhD et al.
Background: ABL-class fusion genes other than BCR–ABL1 have been identified in approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemic cells carrying ABL-class fusions can be targeted successfully by tyrosine-kinase inhibitors. We aimed to establish the baseline characteristics and outcomes of paediatric patients with ABL-class fusion B-cell acute lymphocytic leukaemia in the pre-tyrosine-kinase inhibitor era.Leer más